The ECHDC1 Knockout MES-OV Polyclonal Cells product provides a ready-to-use CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV human ovarian cancer cell line, engineered for disruption of the ECHDC1 gene. This polyclonal knockout model offers a heterogeneous loss-of-function system suitable for studying ECHDC1-dependent processes without clonal selection artifacts. The CRISPR/Cas9-mediated gene disruption targets the coding region of ECHDC1, generating a mixed population of cells with diverse editing outcomes, enabling robust evaluation of gene function in a physiologically relevant ovarian adenocarcinoma background.
The MES-OV host cell line is a well-characterized human ovarian endometrioid adenocarcinoma cell line of epithelial origin, representing a clinically relevant model for ovarian cancer research. MES-OV cells retain key features of ovarian epithelial tumors, including dysregulated proliferation and metabolic reprogramming. Their cancerous phenotype makes them particularly suitable for investigating the intersection between oncogenic signaling and metabolic pathways, especially those involving mitochondrial fatty acid metabolism.
ECHDC1 encodes a mitochondrial ethylmalonyl-CoA decarboxylase that catalyzes the conversion of ethylmalonyl-CoA to butyryl-CoA and carbon dioxide, a critical step in the ethylmalonic acid pathway. This reaction integrates fatty acid beta-oxidation with branched-chain amino acid catabolism. The enzyme is transcriptionally regulated by peroxisome proliferator-activated receptors PPARalpha and PPARdelta, which serve as key upstream regulators. Downstream, ECHDC1 generates butyryl-CoA, a substrate for further beta-oxidation or lipid biosynthesis. ECHDC1 interacts with mitochondrial acyl-CoA dehydrogenase and electron transfer flavoprotein, forming functional complexes that channel electrons into the respiratory chain. Representative pathway components include ethylmalonyl-CoA, ECHDC1, butyryl-CoA, crotonase, and beta-hydroxybutyryl-CoA dehydrogenase.
In the MES-OV ovarian cancer context, ECHDC1 knockout disrupts mitochondrial fatty acid degradation, likely leading to accumulation of ethylmalonic acid and other toxic intermediates. This perturbation can impair energy homeostasis, alter lipid synthesis, and trigger metabolic stress responses, offering a valuable model for dissecting the metabolic vulnerabilities of ovarian cancer cells. As cancer cells often rely on fatty acid oxidation for survival under nutrient-limiting conditions, ECHDC1 loss-of-function may reveal synthetic lethal interactions or novel metabolic dependencies. Moreover, this model bridges cancer metabolism and inherited metabolic disease, as ECHDC1 mutations are linked to ethylmalonic encephalopathy, a severe neurometabolic disorder.
This polyclonal knockout product is ideal for a wide range of research applications, including cancer metabolism studies, metabolic disorder modeling, and drug metabolism profiling. Typical downstream assays include western blotting to confirm protein loss, RT-qPCR for transcript quantification, and targeted metabolomics for ethylmalonic acid measurement. Functional studies can employ fatty acid oxidation assays using radiolabeled or fluorescent substrates, as well as cell viability and proliferation assays under metabolic challenge. The model supports investigation of PPAR signaling, mitochondrial function, and the role of ECHDC1 in tumor cell adaptation. For further information, please contact Ascent Research.
